Bernard Fongang, Ph.D.
Research focuses on developing new computational tools to understand the genetics, genomics and environmental factors driving Alzheimer’s diseases and related disorders. Recent studies have highlighted the association between the gut microbiome, the production of the neurotransmitter serotonin and several neurological disorders. But at the molecular level, how the gut microbiota interacts with the host to produce serotonin and the mechanisms leading to neurological disorders are still not well understood. Research interests include the relationship between serotonin receptors (structurally and functionally), the gut microbiome, the Omics (Genomics, Genetics, Proteomics, Metabolomics) and the risk of dementia, stroke and related neurological endophenotypes. Dr. Fongang’s lab is currently: (i) studying how changes in the gut microbiota are associated with risk of dementia, vascular dementia, and stroke within the Framingham Heart Study; (ii) identifying new genetic loci associated with all-cause dementia and vascular dementia within the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) consortium; (iii) studying the gene expression patterns and regulatory elements associated with cerebral small vessel disease and vascular dementia; (iv) predicting novel druggable interfaces of serotonin receptors involved in Alzheimer’s disease and related disorders.
These projects involve using and developing cutting-edge algorithms and software to individually study the contribution of each factor (Omics, serotonin receptors, gut microbiome) to neurological disorders and integrate the resulting information to identify profiles associated with risk of cognitive impairment, stroke and dementia with the ultimate goal of personalized medicine.